All News

PMR2.jpg

REPLENISH - Secukinumab Works in Polymyalgia Rheumatica

Jack Cush, MD

Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab in adults with polymyalgia rheumatica (PMR).

Read Article
GCA temporal artery

Methylprednisolone plus Methotrexate in Giant Cell Arteritis

Jack Cush, MD

What is the optimal glucocorticoids (GC) regimen in giant cell arteritis (GCA)? Does methotrexate (MTX) work in GCA?  

Read Article
GCA.glossary.wordle

Glossary for Giant Cell Arteritis

Jack Cush, MD

 

Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international experts.

Read Article
Giant-Cell_Vasculitis.jpg

2025 BSR Recommendations for ANCA-associated Vasculitis

Jack Cush, MD

The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) have published a guideline for the management of adults with ANCA-associated vasculitis (AAV); specifically three conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA).

Read Article
RheumNow Podcast square

CKD & Osteoporosis Rx Revisited (7.25.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.

Read Article
PMR,flag

ICYMI: Secukinumab promise in PMR is real

David Liew, FRACP

Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.

Read Article
Conv3.jpg

EULAR 2025 - Day 1 Report

Jack Cush, MD

Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article
PMR,flag

Secukinumab promise in PMR is real

David Liew, FRACP

Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.

Read Article
In case there was any doubt: GCA leads to ischemic vision loss PMR does not #ACR25 ABST0753 @RheumNow https://t.co/mCS9B4Flgl

Links:

David Liew drdavidliew ( View Tweet)
Project from my group & rheum-bound resident Mary Peng! As expected, ischemic vision loss for GCA compared to PMR (HR 5.4) and gen pop (HR 5.6) 😬 NO difference for PMR vs gen pop (aHR 1.10, 95% CI 0.86–1.41) Reassuring for pts w/PMR! #ACR25 @RheumNow Abstr#0753 #ACRBest https://t.co/HKzc7OOzmP

Links:

Mike Putman EBRheum ( View Tweet)
đŸ”„ Hot off the press Prof John Stone shares results from Phase 3 of REPLENISH, out only a few days ago, in which secukinumab met all primary endpoints in treatment of PMR. https://t.co/RlcQWybKrR #ACR25 @RheumNow https://t.co/ucNt2HxJpW

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://t.co/qa9RzmNFU4 https://t.co/dCEkelJzni

Links:

Dr. John Cush RheumNow ( View Tweet)
PMR & GCA not assoc w/ increased mortality, Norway study of 274 isolated PMR (mean age 72 yrs) & 63 GCA (age 72 yrs) pts. After mean F/U 13.7 yrs 96% were deceased. Standardized mortality ratio was Not incr for PMR (0.97)or GCA (1.10), but men w/ PMR had , lower all-cause https://t.co/03lNpQiVYZ
Dr. John Cush RheumNow ( View Tweet)
PMR & GCA not assoc w/ increased mortality, Norway study of 274 isolated PMR (mean age 72 yrs) & 63 GCA (age 72 yrs) pts. After mean F/U 13.7 yrs 96% were deceased. Standardized mortality ratio was Not incr for PMR (0.97)or GCA (1.10), but men w/ PMR had , lower all-cause https://t.co/Mgq920awbD
Dr. John Cush RheumNow ( View Tweet)
Sometimes you hear: “PMR dose steroids don’t really matter” Errrrr
 (You wouldn’t accept this steroid exposure in any other disease. Never) #EULAR2025 POS0139 @RheumNow https://t.co/o6w2RpaGBj

Links:

David Liew drdavidliew ( View Tweet)
In the United States, IL-6R inhibitors have continued to help PMR patients get off steroids. Hopefully more use and more options mean that, in the future, PMR patients get no more steroids than PsA or RA patients #EULAR2025 POS0948 @RheumNow https://t.co/JT7gFDC5rl

Links:

David Liew drdavidliew ( View Tweet)
Secukinumab promise in PMR is real GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of https://t.co/GuD0l7zSfj
Dr. John Cush RheumNow ( View Tweet)
Fast track PMR clinics in Denmark led to more patients seen, and time to referral went down. If we don’t get in early with a right diagnosis (and maybe early steroid-sparing) then PMR patients deteriorate. We shouldn’t let PMR be an end stage disease #EULAR2025 POS0136 @RheumNow https://t.co/pqwveamhJP

Links:

David Liew drdavidliew ( View Tweet)
Secukinumab for PMR? -post hoc analysis of the TitAIN study (phase 2 RCT on new onset/relapsing GCA) showed: -Numerical reduction in patients experiencing PMR symptoms when treated with secukinumab compared to placebo. -Safety profile was similar to the overall GCA study

Adela Castro AdelaCastro222 ( View Tweet)

IL-17 inhibition for PMR? In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperforming steroid taper in the placebo arm. Real promise, will be great to see how the ph3 in PMR (REPLENISH) goes OP0062 #EULAR2025 @RheumNow https://t.co/cisA0GiUx1

Links:

David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×